1
|
Usenko TS, Senkevich KA, Basharova KS, Bezrukova AI, Baydakova GV, Tyurin AA, Beletskaya MV, Kulabukhova DG, Grunina MN, Emelyanov AK, Miliukhina IV, Timofeeva AA, Zakharova EY, Pchelina SN. LRRK2 exonic variants are associated with lysosomal hydrolase activities and lysosphingolipid alterations in Parkinson's disease. Gene 2023; 882:147639. [PMID: 37473971 DOI: 10.1016/j.gene.2023.147639] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2023] [Accepted: 07/11/2023] [Indexed: 07/22/2023]
Abstract
Last data demonstrated that exonic variants of LRRK2 (p.G2019S, p.M1646T) may affect the catalytic activity of lysosomal enzyme glucocerebrosidase (GCase) probably through the phosphorylation of Rab10 protein. We aimed to evaluate an association of LRRK2 exonic variants previously associated with alteration of phosphorylation levels for Rab10Thr73 with PD risk in Russian population and analyze an impact of p.G2019S mutation and selected LRRK2 variants on lysosomal hydrolase activities. LRRK2 variants were determined by full sequencing of LRRK2 in 508 PD patients and 470 controls from Russian population. Activity of lysosomal enzymes (glucocerebrosidase (GCase), alpha-galactosidase A (GLA), acid sphingomyelinase (ASMase) and concentrations of their corresponded substrates (hexosylsphingosine (HexSph), globotriaosylsphingosine (LysoGb3), lysosphingomyelin (LysoSM), respectively) were estimated in 211 PD patients and 179 controls by liquid chromatography with tandem mass spectrometry (LC-MS-MS) in dry blood spots. p.M1646T and p.N2081D were associated with PD (OR = 2.33, CI 95%: 1.1215 to 4.8253, p = 0.023; OR = 1.89, 95%CI: 1.0727 to 3.3313, p = 0.028, respectively) in Russian population. An increased LysoGb3 concentration was found in p.G2019S and p.N2081D LRRK2 carriers among PD patients compared to both PD patients and controls (p.G2019S: p = 0.00086, p = 0.0004, respectively; p.N2081D: p = 0.012, p = 0.0076, respectively). A decreased ASMase activity in p.G2019S LRRK2 carriers among PD patients (p = 0.014) was demonstrated as well. Our study supported possible involvement of LRRK2 dysfunction in an alteration of sphingolipid metabolism in PD.
Collapse
Affiliation(s)
- T S Usenko
- Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre «Kurchatov Institute», Gatchina, Russia; Pavlov First Saint-Petersburg State Medical University, Saint-Petersburg, Russia.
| | - K A Senkevich
- Pavlov First Saint-Petersburg State Medical University, Saint-Petersburg, Russia; The Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal, QC, Canada; Department of Neurology and neurosurgery, McGill University, Montréal, QC, Canada
| | - K S Basharova
- Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre «Kurchatov Institute», Gatchina, Russia
| | - A I Bezrukova
- Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre «Kurchatov Institute», Gatchina, Russia; Pavlov First Saint-Petersburg State Medical University, Saint-Petersburg, Russia
| | - G V Baydakova
- Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre «Kurchatov Institute», Gatchina, Russia; Research Center for Medical Genetics, Moscow, Russia
| | - A A Tyurin
- Pavlov First Saint-Petersburg State Medical University, Saint-Petersburg, Russia
| | - M V Beletskaya
- Pavlov First Saint-Petersburg State Medical University, Saint-Petersburg, Russia
| | - D G Kulabukhova
- Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre «Kurchatov Institute», Gatchina, Russia; Pavlov First Saint-Petersburg State Medical University, Saint-Petersburg, Russia
| | - M N Grunina
- Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre «Kurchatov Institute», Gatchina, Russia
| | - A K Emelyanov
- Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre «Kurchatov Institute», Gatchina, Russia; Pavlov First Saint-Petersburg State Medical University, Saint-Petersburg, Russia
| | - I V Miliukhina
- Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre «Kurchatov Institute», Gatchina, Russia; Pavlov First Saint-Petersburg State Medical University, Saint-Petersburg, Russia; Institute of the Human Brain of RAS, Saint-Petersburg, Russia
| | - A A Timofeeva
- Pavlov First Saint-Petersburg State Medical University, Saint-Petersburg, Russia
| | - E Y Zakharova
- Research Center for Medical Genetics, Moscow, Russia
| | - S N Pchelina
- Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre «Kurchatov Institute», Gatchina, Russia; Pavlov First Saint-Petersburg State Medical University, Saint-Petersburg, Russia
| |
Collapse
|
2
|
Voskoboeva EY, Bookina TM, Semyachkina AN, Mikhaylova SV, Vashakmadze ND, Baydakova GV, Zakharova EY, Kutsev SI. Mucopolysaccharidosis Type I in the Russian Federation and Other Republics of the Former Soviet Union: Molecular Genetic Analysis and Epidemiology. Front Mol Biosci 2022; 8:783644. [PMID: 35141277 PMCID: PMC8819008 DOI: 10.3389/fmolb.2021.783644] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2021] [Accepted: 12/13/2021] [Indexed: 11/13/2022] Open
Abstract
Mutations in the IDUA gene cause deficiency of the lysosomal enzyme alpha-l-iduronidase (IDUA), which leads to a rare disease known as mucopolysaccharidosis type I. More than 300 pathogenic variants of the IDUA gene have been reported to date, but not much is known about the distribution of mutations in different populations and ethnic groups due to the low prevalence of the disease. This article presents the results of a molecular genetic study of 206 patients with mucopolysaccharidosis type I (MPS I) from the Russian Federation (RF) and other republics of the former Soviet Union. Among them, there were 173 Russian (Slavic) patients, 9 Tatars, and 24 patients of different nationalities from other republics of the former Soviet Union. Seventy-three different pathogenic variants in the IDUA gene were identified. The common variant NM_000203.5:c.208C>T was the most prevalent mutant allele among Russian and Tatar patients. The common variant NM_000203.5:c.1205G>A accounted for only 5.8% mutant alleles in Russian patients. Both mutations were very rare or absent in patients from other populations. The pathogenic variant NM_000203.5:c.187C>T was the major allele in patients of Turkic origin (Altaian, Uzbeks, and Kyrgyz). Specific own pathogenic alleles in the IDUA gene were identified in each of these ethnic groups. The identified features are important for understanding the molecular origin of the disease, predicting the risk of its development and creating optimal diagnostic and treatment tools for specific regions and ethnic groups.
Collapse
Affiliation(s)
- E. Yu Voskoboeva
- Federal State Budgetary Scientific Institution, Research Center for Medical Genetics, Moscow, Russia
- *Correspondence: E. Yu Voskoboeva, ; T. M. Bookina, ; A. N. Semyachkina, ; S. V. Mikhaylova, ; N. D. Vashakmadze, ; G. V. Baydakova, ; E. Yu Zakharova, ; S. I. Kutsev,
| | - T. M. Bookina
- Federal State Budgetary Scientific Institution, Research Center for Medical Genetics, Moscow, Russia
- *Correspondence: E. Yu Voskoboeva, ; T. M. Bookina, ; A. N. Semyachkina, ; S. V. Mikhaylova, ; N. D. Vashakmadze, ; G. V. Baydakova, ; E. Yu Zakharova, ; S. I. Kutsev,
| | - A. N. Semyachkina
- Research and Clinical Institute of Pediatrics named after Yuri Veltischev, Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation, Moscow, Russia
- *Correspondence: E. Yu Voskoboeva, ; T. M. Bookina, ; A. N. Semyachkina, ; S. V. Mikhaylova, ; N. D. Vashakmadze, ; G. V. Baydakova, ; E. Yu Zakharova, ; S. I. Kutsev,
| | - S. V. Mikhaylova
- Federal State Budgetary Scientific Institution, Research Center for Medical Genetics, Moscow, Russia
- Detached Structural Unit Russian Children’s Clinical Hospital, Clinical Institute for Pediatrics, Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation Research, Moscow, Russia
- *Correspondence: E. Yu Voskoboeva, ; T. M. Bookina, ; A. N. Semyachkina, ; S. V. Mikhaylova, ; N. D. Vashakmadze, ; G. V. Baydakova, ; E. Yu Zakharova, ; S. I. Kutsev,
| | - N. D. Vashakmadze
- Pediatrics Department, Central Clinical Hospital of the Russian Academy of Sciences, Pirogov Russian National Research Medical University, Moscow, Russia
- *Correspondence: E. Yu Voskoboeva, ; T. M. Bookina, ; A. N. Semyachkina, ; S. V. Mikhaylova, ; N. D. Vashakmadze, ; G. V. Baydakova, ; E. Yu Zakharova, ; S. I. Kutsev,
| | - G. V. Baydakova
- Federal State Budgetary Scientific Institution, Research Center for Medical Genetics, Moscow, Russia
- *Correspondence: E. Yu Voskoboeva, ; T. M. Bookina, ; A. N. Semyachkina, ; S. V. Mikhaylova, ; N. D. Vashakmadze, ; G. V. Baydakova, ; E. Yu Zakharova, ; S. I. Kutsev,
| | - E. Yu Zakharova
- Federal State Budgetary Scientific Institution, Research Center for Medical Genetics, Moscow, Russia
- *Correspondence: E. Yu Voskoboeva, ; T. M. Bookina, ; A. N. Semyachkina, ; S. V. Mikhaylova, ; N. D. Vashakmadze, ; G. V. Baydakova, ; E. Yu Zakharova, ; S. I. Kutsev,
| | - S. I. Kutsev
- Federal State Budgetary Scientific Institution, Research Center for Medical Genetics, Moscow, Russia
- *Correspondence: E. Yu Voskoboeva, ; T. M. Bookina, ; A. N. Semyachkina, ; S. V. Mikhaylova, ; N. D. Vashakmadze, ; G. V. Baydakova, ; E. Yu Zakharova, ; S. I. Kutsev,
| |
Collapse
|
3
|
Usenko TS, Senkevich KA, Bezrukova AI, Baydakova GV, Basharova KS, Zhuravlev AS, Gracheva EV, Kudrevatykh AV, Miliukhina IV, Krasakov IV, Khublarova LA, Fursova IV, Zakharov DV, Timofeeva AA, Irishina YA, Palchikova EI, Zalutskaya NM, Emelyanov AK, Zakharova EY, Pchelina SN. Impaired Sphingolipid Hydrolase Activities in Dementia with Lewy Bodies and Multiple System Atrophy. Mol Neurobiol 2022; 59:2277-2287. [PMID: 35066761 DOI: 10.1007/s12035-021-02688-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2021] [Accepted: 12/08/2021] [Indexed: 11/28/2022]
Abstract
The synucleinopathies are a group of neurodegenerative diseases characterized by the oligomerization of alpha-synuclein protein in neurons or glial cells. Recent studies provide data that ceramide metabolism impairment may play a role in the pathogenesis of synucleinopathies due to its influence on alpha-synuclein accumulation. The aim of the current study was to assess changes in activities of enzymes involved in ceramide metabolism in patients with different synucleinopathies (Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA)). The study enrolled 163 PD, 44 DLB, and 30 MSA patients as well as 159 controls. Glucocerebrosidase, alpha-galactosidase, acid sphingomyelinase enzyme activities, and concentrations of the corresponding substrates (hexosylsphingosine, globotriaosylsphingosine, lysosphingomyelin) were measured by liquid chromatography tandem-mass spectrometry in blood. Expression levels of GBA, GLA, and SMPD1 genes encoding glucoceresobridase, alpha-galactosidase, and acid sphingomyelinase enzymes, correspondently, were analyzed by real-time PCR with TaqMan assay in CD45 + blood cells. Increased hexosylsphingosine concentration was observed in DLB and MSA patients in comparison to PD and controls (p < 0.001) and it was associated with earlier age at onset (AAO) of DLB (p = 0.0008). SMPD1 expression was decreased in MSA compared to controls (p = 0.015). Acid sphingomyelinase activity was decreased in DLB, MSA patients compared to PD patients (p < 0.0001, p < 0.0001, respectively), and in MSA compared to controls (p < 0.0001). Lower acid sphingomyelinase activity was associated with earlier AAO of PD (p = 0.012). Our data support the role of lysosomal dysfunction in the pathogenesis of synucleinopathies, namely, the pronounced alterations of lysosomal activities involved in ceramide metabolism in patients with MSA and DLB.
Collapse
Affiliation(s)
- T S Usenko
- Petersburg Nuclear Physics Institute Named By B.P. Konstantinov of National Research Centre «Kurchatov Institute», 1, mkr. Orlova roshcha, 188300, Gatchina, Russia. .,Pavlov First Saint-Petersburg State Medical University, L'va Tolstogo str. 6-8, 197022, St. Petersburg, Russia.
| | - K A Senkevich
- Petersburg Nuclear Physics Institute Named By B.P. Konstantinov of National Research Centre «Kurchatov Institute», 1, mkr. Orlova roshcha, 188300, Gatchina, Russia.,Pavlov First Saint-Petersburg State Medical University, L'va Tolstogo str. 6-8, 197022, St. Petersburg, Russia
| | - A I Bezrukova
- Petersburg Nuclear Physics Institute Named By B.P. Konstantinov of National Research Centre «Kurchatov Institute», 1, mkr. Orlova roshcha, 188300, Gatchina, Russia
| | - G V Baydakova
- Research Center for Medical Genetics, Moskvorechie str. 1, Moscow, 115478, Russia
| | - K S Basharova
- Petersburg Nuclear Physics Institute Named By B.P. Konstantinov of National Research Centre «Kurchatov Institute», 1, mkr. Orlova roshcha, 188300, Gatchina, Russia
| | - A S Zhuravlev
- Petersburg Nuclear Physics Institute Named By B.P. Konstantinov of National Research Centre «Kurchatov Institute», 1, mkr. Orlova roshcha, 188300, Gatchina, Russia
| | - E V Gracheva
- Institute of the Human Brain of RAS, 9, Pavlova str, St. Petersburg, 197376, Russia
| | - A V Kudrevatykh
- Institute of the Human Brain of RAS, 9, Pavlova str, St. Petersburg, 197376, Russia
| | - I V Miliukhina
- Pavlov First Saint-Petersburg State Medical University, L'va Tolstogo str. 6-8, 197022, St. Petersburg, Russia.,Institute of the Human Brain of RAS, 9, Pavlova str, St. Petersburg, 197376, Russia
| | - I V Krasakov
- The Nikiforov Russian Center of Emergency and Radiation Medicine, Optikov str. 54, 197082, St. Petersburg, Russia
| | - L A Khublarova
- V.M. Bekhterevs National Medical Research Center Psychiatry and Neurology, 3 Bekhterev str., 192019, St. Petersburg, Russia
| | - I V Fursova
- V.M. Bekhterevs National Medical Research Center Psychiatry and Neurology, 3 Bekhterev str., 192019, St. Petersburg, Russia
| | - D V Zakharov
- V.M. Bekhterevs National Medical Research Center Psychiatry and Neurology, 3 Bekhterev str., 192019, St. Petersburg, Russia
| | - A A Timofeeva
- Pavlov First Saint-Petersburg State Medical University, L'va Tolstogo str. 6-8, 197022, St. Petersburg, Russia
| | - Y A Irishina
- Institute of the Human Brain of RAS, 9, Pavlova str, St. Petersburg, 197376, Russia
| | - E I Palchikova
- V.M. Bekhterevs National Medical Research Center Psychiatry and Neurology, 3 Bekhterev str., 192019, St. Petersburg, Russia
| | - N M Zalutskaya
- V.M. Bekhterevs National Medical Research Center Psychiatry and Neurology, 3 Bekhterev str., 192019, St. Petersburg, Russia
| | - A K Emelyanov
- Petersburg Nuclear Physics Institute Named By B.P. Konstantinov of National Research Centre «Kurchatov Institute», 1, mkr. Orlova roshcha, 188300, Gatchina, Russia.,Pavlov First Saint-Petersburg State Medical University, L'va Tolstogo str. 6-8, 197022, St. Petersburg, Russia
| | - E Y Zakharova
- Research Center for Medical Genetics, Moskvorechie str. 1, Moscow, 115478, Russia
| | - S N Pchelina
- Petersburg Nuclear Physics Institute Named By B.P. Konstantinov of National Research Centre «Kurchatov Institute», 1, mkr. Orlova roshcha, 188300, Gatchina, Russia.,Pavlov First Saint-Petersburg State Medical University, L'va Tolstogo str. 6-8, 197022, St. Petersburg, Russia.,Institute of Experimental Medicine, 12, Acad. Pavlov Str, 197376, Saint-Petersburg, Russia
| |
Collapse
|
4
|
Abstract
The paper describes a case of a perinatal lethal Gaucher disease in a 29-week-old fetus with non-immune hydrops, facial dysmorphia, hepatosplenomegaly, and hypoplasia of cerebellum and pons. Gaucher cells were found in the lymph nodes, spleen, lungs, thymus, cerebellum, and bone marrow. No storage cells have been detected in the placenta. There was a significant placental weight increase due to swelling. The diagnosis of Gaucher disease was confirmed by biochemical analysis (deficiency of glucocerebrosidase activity and sharply increased hexanoylsphingosine concentration) and molecular genetic techniques (the presence of two mutations of the GBA gene). Our observation shows that characteristic histologic signs of disease can be detected at early stages of development.
Collapse
Affiliation(s)
- I N Voloshchuk
- Moscow Regional Research Institute of Obstetrics and Gynecology of the Ministry of Health of the Moscow Region, Moscow Region, Russia.,Russian Medical Academy of Continuous Professional Education of the Ministry of Health of Russia, Moscow, Russia
| | - I V Barinova
- Moscow Regional Research Institute of Obstetrics and Gynecology of the Ministry of Health of the Moscow Region, Moscow Region, Russia
| | - E N Andreeva
- Moscow Regional Research Institute of Obstetrics and Gynecology of the Ministry of Health of the Moscow Region, Moscow Region, Russia
| | - A R Fattakhov
- Moscow Regional Research Institute of Obstetrics and Gynecology of the Ministry of Health of the Moscow Region, Moscow Region, Russia
| | - G V Baydakova
- Federal State Budgetary Scientific Institution Research Centre for Medical Genetics named after Academician N.P. Bochkov, Moscow, Russia
| | - E Yu Zakharova
- Federal State Budgetary Scientific Institution Research Centre for Medical Genetics named after Academician N.P. Bochkov, Moscow, Russia
| |
Collapse
|
5
|
Kopytova AE, Rychkov GN, Nikolaev MA, Baydakova GV, Cheblokov AA, Senkevich KA, Bogdanova DA, Bolshakova OI, Miliukhina IV, Bezrukikh VA, Salogub GN, Sarantseva SV, Usenko TC, Zakharova EY, Emelyanov AK, Pchelina SN. Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism. Parkinsonism Relat Disord 2021; 84:112-121. [PMID: 33609962 DOI: 10.1016/j.parkreldis.2021.02.003] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/14/2020] [Revised: 01/11/2021] [Accepted: 02/01/2021] [Indexed: 12/24/2022]
Abstract
Mutations in the glucocerebrosidase gene (GBA) encoding the lysosomal enzyme glucocerebrosidase (GCase) cause Gaucher disease (GD) and are the most commonly known genetic risk factor for Parkinson disease (PD). Ambroxol is one of the most effective pharmacological chaperones of GCase. Fourteen GD patients, six PD patients with mutations in the GBA gene (GBA-PD), and thirty controls were enrolled. GCase activity and hexosylsphingosine (HexSph) concentration were measured in dried blood and macrophage spots using liquid chromatography coupled with tandem mass spectrometry. The effect of ambroxol on GCase translocation to lysosomes was assessed using confocal microscopy. The results showed that ambroxol treatment significantly increased GCase activity in cultured macrophages derived from patient blood monocytic cell (PBMC) of GD (by 3.3-fold) and GBA-PD patients (by 3.5-fold) compared to untreated cells (p < 0.0001 and p < 0.0001, respectively) four days after cultivation. Ambroxol treatment significantly reduced HexSph concentration in GD (by 2.1-fold) and GBA-PD patients (by 1.6-fold) (p < 0.0001 and p < 0.0001, respectively). GD macrophage treatment resulted in increased GCase level and increased enzyme colocalization with the lysosomal marker LAMP2. The possible binding modes of ambroxol to mutant GCase carrying N370S amino acid substitution at pH 4.7 were examined using molecular docking and molecular dynamics simulations. The ambroxol position characterized by minimal binding free energy was observed in close vicinity to the residue, at position 370. Taken together, these data showed that PBMC-derived macrophages could be used for assessing ambroxol therapy response for GD patients and also for GBA-PD patients.
Collapse
Affiliation(s)
- A E Kopytova
- Petersburg Nuclear Physics Institute Named By B.P. Konstantinov of National Research Center «Kurchatov Institute», Gatchina, Russia.
| | - G N Rychkov
- Petersburg Nuclear Physics Institute Named By B.P. Konstantinov of National Research Center «Kurchatov Institute», Gatchina, Russia; Peter the Great St.Petersburg Polytechnic University, Saint-Petersburg, Russia; Kurchatov Genome Center - PNPI, Gatchina, Russia
| | - M A Nikolaev
- Petersburg Nuclear Physics Institute Named By B.P. Konstantinov of National Research Center «Kurchatov Institute», Gatchina, Russia; First Pavlov State Medical University of St. Petersburg, Saint-Petersburg, Russia
| | - G V Baydakova
- Research Center for Medical Genetics, Moscow, Russia
| | - A A Cheblokov
- Petersburg Nuclear Physics Institute Named By B.P. Konstantinov of National Research Center «Kurchatov Institute», Gatchina, Russia
| | - K A Senkevich
- Petersburg Nuclear Physics Institute Named By B.P. Konstantinov of National Research Center «Kurchatov Institute», Gatchina, Russia; First Pavlov State Medical University of St. Petersburg, Saint-Petersburg, Russia
| | - D A Bogdanova
- Petersburg Nuclear Physics Institute Named By B.P. Konstantinov of National Research Center «Kurchatov Institute», Gatchina, Russia
| | - O I Bolshakova
- Petersburg Nuclear Physics Institute Named By B.P. Konstantinov of National Research Center «Kurchatov Institute», Gatchina, Russia
| | - I V Miliukhina
- Petersburg Nuclear Physics Institute Named By B.P. Konstantinov of National Research Center «Kurchatov Institute», Gatchina, Russia; Institute of Experimental Medicine, Saint-Petersburg, Russia; First Pavlov State Medical University of St. Petersburg, Saint-Petersburg, Russia
| | - V A Bezrukikh
- Almazov National Medical Research Centre, Saint-Petersburg, Russia
| | - G N Salogub
- Almazov National Medical Research Centre, Saint-Petersburg, Russia
| | - S V Sarantseva
- Petersburg Nuclear Physics Institute Named By B.P. Konstantinov of National Research Center «Kurchatov Institute», Gatchina, Russia
| | - T C Usenko
- Petersburg Nuclear Physics Institute Named By B.P. Konstantinov of National Research Center «Kurchatov Institute», Gatchina, Russia; First Pavlov State Medical University of St. Petersburg, Saint-Petersburg, Russia
| | - E Y Zakharova
- Research Center for Medical Genetics, Moscow, Russia
| | - A K Emelyanov
- Petersburg Nuclear Physics Institute Named By B.P. Konstantinov of National Research Center «Kurchatov Institute», Gatchina, Russia; Institute of Experimental Medicine, Saint-Petersburg, Russia; First Pavlov State Medical University of St. Petersburg, Saint-Petersburg, Russia
| | - S N Pchelina
- Petersburg Nuclear Physics Institute Named By B.P. Konstantinov of National Research Center «Kurchatov Institute», Gatchina, Russia; Institute of Experimental Medicine, Saint-Petersburg, Russia; First Pavlov State Medical University of St. Petersburg, Saint-Petersburg, Russia
| |
Collapse
|
6
|
Semyachkina AN, Voskoboeva EY, Zakharova EY, Nikolaeva EA, Kanivets IV, Kolotii AD, Baydakova GV, Kharabadze MN, Kuramagomedova RG, Melnikova NV. Case report: a rare case of Hunter syndrome (type II mucopolysaccharidosis) in a girl. BMC Med Genet 2019; 20:66. [PMID: 31046699 PMCID: PMC6498611 DOI: 10.1186/s12881-019-0807-x] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/15/2018] [Accepted: 04/16/2019] [Indexed: 11/10/2022]
Abstract
BACKGROUND Hunter syndrome (mucopolysaccharidosis type II) is a recessive X-linked disorder due to mutations in the iduronate 2-sulfatase (IDS) gene. The IDS gene encodes a lysosomal enzyme, iduronate 2-sulfatase. The disease occurs almost exclusively in males. However, in the literature, 12 cases of the disease in females are known due to structural anomalies, a non-random chromosome X inactivation or chromosome X monosomy. The purpose of this article is to demonstrate a rare case of Hunter syndrome in a girl caused by a mutation in the IDS gene inherited from the mother and the presence of chromosome X of paternal origin, partially deleted in the long arm region - 46,X,del(X)(q22.1). CASE PRESENTATION Girl M., 4 years old, entered the hospital with growth retardation, pain in the lower limbs, and joint stiffness, noted from the age of 18 months. After the karyotype analysis, which revealed a partial deletion of the long arm of chromosome X - 46, X, del (X) (q 22.1), Turner syndrome was diagnosed. However, due to the hurler-like facial phenotype, Hurler syndrome or type I mucopolysaccharidosis (MPS) was suspected. The study of lysosomal enzymes showed normal alpha-L-iduronidase activity and a sharp decrease in the activity of iduronate sulfatase in the blood: 0.001 μM/l/h, at a rate of 2.5-50 μM/l/h. Molecular genetic analysis revealed a hemizygous deletion in the IDS gene, which was not registered in the international Human Gene Mutation Database (HGMD) professional. This deletion was not detected in the girl's father, but was detected in her mother in the heterozygous state. CONCLUSIONS Thus, the girl confirmed comorbidity - Turner syndrome with a partial deletion of the long arm of chromosome X of paternal origin, affecting the Xq28 region (localization of the IDS gene), and Hunter syndrome due to a deletion of the IDS gene inherited from the mother. The structural defect of chromosome X in the girl confirmed the hemizygous state due to the mutation in the IDS gene, which has led to the formation of the clinical phenotype of Hunter syndrome.
Collapse
Affiliation(s)
- A N Semyachkina
- Department of Clinical Genetics, Research and Clinical Institute of Pediatrics named after Yuri Veltischev of the Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, 2 Taldomskaya St, Moscow, 125412, Russia.
| | - E Y Voskoboeva
- Research Centre for Medical Genetics RAN, 1 Moskvorechie St, Moscow, 115522, Russia
| | - E Y Zakharova
- Research Centre for Medical Genetics RAN, 1 Moskvorechie St, Moscow, 115522, Russia
| | - E A Nikolaeva
- Department of Clinical Genetics, Research and Clinical Institute of Pediatrics named after Yuri Veltischev of the Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, 2 Taldomskaya St, Moscow, 125412, Russia
| | - I V Kanivets
- Genomed, Moscow, 8/5 Podolskoye Shosse, Moscow, Russia
| | - A D Kolotii
- Department of Clinical Genetics, Research and Clinical Institute of Pediatrics named after Yuri Veltischev of the Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, 2 Taldomskaya St, Moscow, 125412, Russia
| | - G V Baydakova
- Research Centre for Medical Genetics RAN, 1 Moskvorechie St, Moscow, 115522, Russia
| | - M N Kharabadze
- Department of Clinical Genetics, Research and Clinical Institute of Pediatrics named after Yuri Veltischev of the Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, 2 Taldomskaya St, Moscow, 125412, Russia
| | - R G Kuramagomedova
- Department of Clinical Genetics, Research and Clinical Institute of Pediatrics named after Yuri Veltischev of the Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, 2 Taldomskaya St, Moscow, 125412, Russia
| | - N V Melnikova
- Kuban Medical and Genetics Center, 167, Pervogo Maya St, Krasnodar, Russia
| |
Collapse
|
7
|
Tsygankova P, Zakharova EY, Baydakova GV. Gene symbol: ACADVL. Disease: Very long chain acyl-CoA dehydrogenase deficiency. Hum Genet 2008; 124:299. [PMID: 18846621] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Affiliation(s)
- Polina Tsygankova
- Research Centre for Medical Genetics, Laboratory of inherited metabolic disorders, 115478 Moscow, Russian Federation.
| | | | | |
Collapse
|